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Abstract 18	  
In this article we critically assess evidence for the existence of a family of anti-angiogenic 19	  
Vegfaxxxb transcripts, arising from the use of a phylogenetically conserved alternative distal 20	  
splice site within exon 8 of the VEGFA gene. We explain that prior evidence for Vegfaxxxb 21	  
transcripts in tissues rests heavily upon flawed RT-PCR methodologies, with the extensive use of 22	  
5ˊ-tailing in primer design being the main issue. Furthermore, our analysis of large RNA-seq 23	  
datasets (human and ovine) fails to identify a single Vegfaxxxb transcript. Therefore, we 24	  
challenge the very existence of Vegfaxxxb transcripts, which further questions the physiological 25	  
2	  
	  
relevance of studies based on the use of “anti-VEGFAxxxb” antibodies. Our analysis has 26	  
implications for the proposed therapeutic use of isoform-specific anti-VEGFA strategies for 27	  
treating cancer and retinopathies. 28	  
 29	  
Classical angiogenic VEGFA isoforms 30	  
VEGFA is a key regulator of vascular homeostasis and therapeutic target in pathological 31	  
angiogenesis. The VEGFA gene is subject to alternative splicing, which occurs primarily in 32	  
exons 6 and 7 (Figure 1) [1-4]. In humans, the most abundant mature translated isoform is 33	  
VEGFA165 (i.e. this isoform comprises 165 amino acids), which lacks exon 6. Three other 34	  
isoforms are present in moderate/high amounts: VEGFA121, which lacks both exons 6 and 7, 35	  
VEGFA189, which includes exon 7 but uses an alternative 5ˊ-donor site in exon 6 and 36	  
VEGFA206, which includes both exons 6 and 7 (Figure 1B & Figure 1E). These VEGFA 37	  
isoforms exist in other species, including mouse, sheep and cattle, but they are one amino acid 38	  
shorter than their human counterparts. Other less abundant isoforms have been described, some 39	  
of which are also generated through alternative splicing within exons 6/7 (VEGFA145, 40	  
VEGFA148, VEGFA183). The amino acid stretches encoded by exons 6 and 7 are enriched in 41	  
clusters of basic amino acids, which confer VEGFA with the ability to bind the extracellular 42	  
matrix and thus mitigate its diffusion. Consequently, VEGFA121 is highly diffusible, while 43	  
VEGFA189 and VEGFA206 remain bound to the extracellular matrix and VEGFA165 has 44	  
intermediate matrix binding characteristics [1-4]. VEGFA isoforms bind with varying affinities 45	  
to the tyrosine kinase receptors VEGFR1 and VEGFR2 and recruit the co-receptor Neuropilin 1 46	  
to activate intracellular signaling pathways as illustrated on the left side of Figure 1G [5,6]. 47	  
Critically, all VEGFA isoforms promote angiogenesis, which is key to the progression of 48	  






Non-classical anti-angiogenic VEGFAxxxb and VEGF-Ax isoforms 53	  
In 2002, Bates and colleagues [8] reported a novel human Vegfa splice variant, generated 54	  
through use of an alternative distal splice site within the last exon of the VEGFA gene, exon 8 55	  
(see Figure 1C and Figure 1D). The transcript was dubbed Vegfa165b. Follow-up studies 56	  
suggested that the encoded VEGFA165b protein product belongs to an entire VEGFAxxxb 57	  
family of proteins, which are derived from transcripts that use the distal splice site in exon 8 58	  
(Figure 1E) and bear anti-angiogenic properties [3,9-14]. From a functional standpoint, 59	  
VEGFA165b was shown to bind to VEGFR2 with the same affinity as VEGFA165 [15-18] but 60	  
failed to bind to Neuropilin 1 as illustrated on the right part of Figure 1G [16,17,19]. 61	  
VEGFA165b induces VEGFR2 tyrosine phosphorylation in a dose-dependent manner, albeit less 62	  
efficiently and more transiently than VEGFA165 [15-17,19]. However, this impaired ability of 63	  
VEGFA165b to activate intracellular signaling pathways may not apply to all cell types [20,21]. 64	  
Another isoform, dubbed VEGF-Ax, has recently been described [22]. VEGF-Ax arise from 65	  
programmed translational read-through, such that the stop-codon of classical VEGFA isoforms 66	  
leads to insertion of a Serine residue, and the in-frame stop-codon of putative VEGFAxxxb 67	  
isoforms is used instead. In other words, VEGF-Ax and VEGFAxxxb isoforms would share the 68	  
same C-term sequence. However, the in vivo existence of VEGF-Ax is disputed and in vitro data 69	  
demonstrate pro-angiogenic properties [23].  70	  
 71	  
Existence of VEGFAxxxb isoforms: clinical implications  72	  
Overall, VEGFA165b appears to behave as a partial agonist [16], which competes with 73	  
VEGFA165 for VEGFR2/Neuropilin 1 binding. This may explain the reduced angiogenic 74	  
potential of VEGFA165b [20,23,24]. Based on this, Harper & Bates proposed a model in which 75	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the balance between endogenous levels of angiogenic VEGFAxxx and anti-angiogenic 76	  
VEGFAxxxb isoforms sets the angiogenic potential of a tissue [3]. They further proposed that 77	  
VEGFAxxxb isoforms predominate in many normal cells and tissues where they can amount to 78	  
more than 50% of total VEGFA protein [10]. In normal colonic tissues in particular, 79	  
VEGFAxxxb variants have been reported to comprise as much as 95% of all VEGFA [25]. The 80	  
proposed use of the alternative distal splice site within exon 8 is therefore not a rare event, and 81	  
its prevalence implies major physiological relevance. However, in pathological conditions such 82	  
as cancer and retinopathies, VEGFAxxxb levels appear to be substantially downregulated. 83	  
Considering the crucial role of VEGFA in angiogenesis of various cancers and retinopathies 84	  
[1,26-28] such a finding may have broad clinical implications.  85	  
 86	  
Indeed, current strategies to target VEGFA, such as the anti-VEGFA antibody bevacizumab, 87	  
Avastin®) or aflibercept (VEGFA-trap), would indiscriminately inhibit both angiogenic 88	  
VEGFAxxx and anti-angiogenic VEGFAxxxb isoforms. Bates et al showed that targeting 89	  
VEGFA in colorectal cancer was more efficient if endogenous levels of VEGFAxxxb were low 90	  
and proposed that assessment of the ratio of VEGFAxxxb to VEGFAxxx could potentially 91	  
predict response to bevacizumab and other therapies directed against VEGFA [3]. Therefore, 92	  
modification of VEGFA splicing to alter the VEGFAxxxb/VEGFAxxx balance, or development 93	  
of compounds to target only VEGAxxx isoforms, may have therapeutic value for treating 94	  
cancers and retinopathies [29]. In 2009, D.O. Bates and S.J. Harper filed a patent for the “Novel 95	  
use of VEGFAxxxb”, which covers the use of these isoforms (primarily VEGFA165b) for 96	  
several potential therapeutic applications. 97	  
 98	  
The Controversy: Do VEGFAxxxb isoforms really exist? 99	  
5	  
	  
Despite a substantial amount of literature reporting evidence for the existence of VEGFAxxxb 100	  
isoforms, the VEGFA scientific community is divided on this issue. We and others have yet to 101	  
detect these isoforms in normal and pathological tissues and have thus concluded that 102	  
VEGFAxxxb isoforms, if they do exist, are likely not of physiological relevance. In recent 103	  
reviews on VEGFA signaling and disease, VEGFAxxxb biology is largely disregarded [7] or 104	  
notably overlooked [30]. Until now, evidence for the existence of VEGFAxxxb isoforms has 105	  
been provided through PCR-based approaches and studies using an antibody generated against 106	  
the sequence TCRSLTRKD encoded by putative exon 8b of the human Vegfa gene. Here, we 107	  
critically review and reassess the evidence which led to the assumption that "there is an 108	  
important role for VEGFAxxxb isoforms in normal physiology" [10]. Our own findings [31-33] 109	  
and a thorough analysis of the literature has led us to question and re-evaluate the existence of 110	  
Vegfaxxxb transcripts 111	  
 112	  
Absence of Evidence: Detection of Vegfaxxxb transcripts with flanking primers. 113	  
Since alternative splicing affects exons 6, 7 and 8, the best way to identify all Vegfa splice 114	  
variants is to use primers flanking these regions. Such a primer design is expected to amplify all 115	  
Vegfa isoforms. To do so, the forward primer has to be located within exons 1-5 (common to all 116	  
splice variants) and the reverse primer located downstream of the putative exon 8b splice site. If 117	  
Vegfaxxx and Vegfaxxxb splice variants are sister families and Vegfaxxxb mRNAs represent a 118	  
large fraction of total Vegfa mRNA, at least in normal tissues [10], a standard RT-PCR with the 119	  
aforementioned primers would be expected to yield at least 6 main products/bands corresponding 120	  
to mRNA for the major isoforms VEGFA189, VEGFA165 and VEGFA121 and their "sister 121	  
bands" for VEGFA189b, VEGFA165b and VEGFA121b, albeit at different abundances. The 122	  
bands encoding Vegfaxxxb isoforms would be 66bp shorter than their respective counterparts 123	  
(see Figure 1D) thereby yielding 3 "doublets" easily discernible on an agarose gel. However, in 124	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their seminal paper reporting on the discovery of Vegfa165b [8], Bates et al stated that "PCR of 125	  
the full-length product using primers V165K (complementary to the translation initiation site of 126	  
the other isoforms of VEGF) and V165X (a primer downstream of the original 3ˊ-UTR) resulted 127	  
in one strong band at ~670bp”. Considering the strategy used, it is difficult to explain why other 128	  
Vegfaxxx and Vegfaxxxb transcripts were not identified by this initial study. Indeed, as mentioned 129	  
above, at least 6 bands, corresponding to the 3 “doublets” (VEGFA189/189b, VEGFA165/165b 130	  
and VEGFA121/121b), should have been observed by agarose electrophoresis of PCR products. 131	  
Furthermore, nested PCR with a 3ˊ-UTR and exon 7a primers resulted in a strong band at 132	  
~130bp confirming that the full-length was VEGFA165b".  133	  
 134	  
We and others have adopted this strategy in order to identify Vegfaxxxb transcripts in human, 135	  
mouse, sheep and cattle but failed to identify Vegfa165b mRNA - or other Vegfaxxxb products 136	  
[22,31,33,34]. Instead, only three bands were observed (see Figure 1B and Figure 1F) and 137	  
sequencing of the PCR products showed unequivocally that they encoded VEGFA189, 138	  
VEGFA165 and VEGFA121 [22,24,32-34]. Therefore, an unbiased and straightforward RT-PCR 139	  
strategy to simultaneously amplify all Vegfa isoforms failed to support the existence of 140	  
Vegfaxxxb mRNA. Since these flanking primers could not discriminate Vegfaxxx from putative 141	  
Vegfaxxxb transcripts, isoform-specific primers were developed.  142	  
 143	  
Detection of Vegfaxxxb-like transcripts with “isoform-specific primers”: a tale of a tail.  144	  
Over time, there has been a considerable drift in the design of primers aimed at the specific 145	  
identification of Vegfa165b that span the exon 7 – exon 8b splice site. However, in most studies, 146	  
the exon 7-specific stretch has been greatly lengthened at the expense of the exon 8b-specific 147	  
region (see Figure 2A and Table S1). Since exon 7 would be shared by both Vegfa165 and 148	  
Vegfa165b, the isoform-specificity of these reverse primers is questionable. Technically, the 149	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necessary and sufficient primer design to allow specific detection of Vegfa165b mRNA would 150	  
include the shortest possible 3ˊ-anchor within exon 7; based on standard PCR principles (see 151	  
Figure 3) one base specific to exon 7 on the 3ˊ-end of the primer would suffice. However, in the 152	  
case of the human sequence, since the AT motif would be shared by both Vegfa165 and 153	  
Vegfa165b (see Figure 1) this means that the last 3bp at the 3ˊ-end of such a primer would 154	  
anneal to exon 7 with the last nucleotide discriminating between Vegfa165 and Vegfa165b 155	  
isoforms (see Figure 2A, Primer P1). Surprisingly, this most simple strategy has never been used 156	  
in the literature.  157	  
 158	  
Rather than using such a “minimal and sufficient” primer design for detection of Vegfaxxxb 159	  
isoforms, the design of the primer has been "adapted". The initial design, published in the 160	  
seminal Vegfa165b paper by Bates et al [8], comprised of 7bp complementary to either Vegfa165 161	  
or Vegfa165b (Figure 2A, Primer P2). This primer has been used in a number of subsequent 162	  
studies by the same group [15,35-39] and other research teams that used RT-PCR to demonstrate 163	  
the existence of Vegfaxxxb transcripts [40,41]. In 2007, Ribeiro et al used a modified version of 164	  
this primer for their studies in pig [42], with 9bp complementary to either Vegfa165 or 165	  
Vegfa165b (Figure 2A, Primer P3), while Baba et al used 8bp complementary to either 166	  
Vegfa165 or Vegfa165b [43]. Overall, the number of bases complementary to either Vegfa165 or 167	  
Vegfa165b has been on the rise since 2007: 13 bp in 2008 ([44]; Figure 2A, Primer P4), 14bp in 168	  
2009 (study in rat; [45]) and 15bp in 2010-2011 ([46,47]; Figure 2A, Primer P5). Finally, a 169	  
design including no less than 17bp common to both Vegfa165 or Vegfa165b was proposed to 170	  
specifically amplify Vegfa165b mRNA ([48]; Figure 2A, Primer P6). We also note that the same 171	  
methodology has been used for the design of a Vegfa165b-specific forward primer, which 172	  
includes 14bp that would also anneal to Vegfa165 ([34]; Figure 2A, Primer P7). This approach 173	  




We demonstrated that this primer design is responsible for PCR artefacts, due to 5ˊ-tailing, that 176	  
could be mis-interpreted as Vegfaxxxb transcripts ([31,33]; see Figure 3). The conclusion of 177	  
these studies was that PCR products correspond to putative Vegfaxxxb transcripts only because 178	  
primers were designed to include on their 5ˊ-end a few bases of the Vegfaxxxb sequence itself. 179	  
This method has been used for decades, most often to add restriction sites to aid cloning. Good 180	  
examples are provided by Catena et al [20] and Ganta et al [49], who flanked the 5ˊ-end of their 181	  
reverse primers with an HindIII (or BamHI, respectively) restriction site followed by the entire 182	  
predicted sequence for the putative exon 8b and 20-23 bp complementary to either exon 5 or 183	  
exon 7 in order to generate synthetic expression vectors for Vegfa121b or Vegfa165b (see Table 184	  
S1). We demonstrated that Vegfa amplification by RT-PCR could be obtained when bases 185	  
"specific for Vegfaxxxb" on the primer 5ˊ-end were changed to a GGGGG or an AAAAA stretch 186	  
[33]. The minimal primer design we defined to be sufficient to obtain artefactual Vegfaxxxb-like 187	  
PCR products perfectly matches the P4 primer described above ([33]; see Figure 2B). Therefore, 188	  
studies which claimed identification of Vegfaxxxb transcripts using primers with ≥13bp common 189	  
to Vegfaxxx and putative Vegfaxxxb mRNA do not reach required standards of evidence, and 190	  
their conclusions should be re-evaluated. 191	  
 192	  
By 2013, the use of the questionable P4 primer design had become widespread in the literature 193	  
[44,50-52]. This design constitutes a significant departure from initial studies that used the P2 194	  
primer with 7bp complementarity to either Vegfa165 or Vegfa165b. The reasons for this drift in 195	  
primer design are not clear. However, as early as 2006, Bates and colleagues [37] acknowledged 196	  
that "…RT-PCR is not quantitative and it has not been possible so far to develop isoform-197	  
specific qPCR, due to the lack of exon-specific sequences". It seems surprising that primers 198	  
9	  
	  
deemed suitable for specific detection of Vegfa165b in standard RT-PCR would not be suitable 199	  
for qPCR.  200	  
In conclusion, the detection of “Vegfaxxxb-like” transcripts could be explained by the use of 201	  




Bioinformatic analysis of alternative splicing: absence of evidence for Vegfaxxxb isoforms. 206	  
Using AVISPA, a tool for prediction and analysis of alternative splicing, Barash et al reported 207	  
that "prediction of other splice variations of Vegfa, such as the 3ˊ splice site variation in exon 8, 208	  
are currently not supported by the tool [53]	   ". Another splice site prediction software ([54]; 209	  
available at http://www.fruitfly.org/seq_tools/splice.html) identified the canonical acceptor 210	  
splice site of exon 8 (score of 0.97) but failed to identify the putative exon 8b splice site. 211	  
Therefore, efficient in silico tools do not currently support the existence of the proposed distal 212	  
splice site in exon 8 of the Vegfa gene. 213	  
 214	  
Detection of the Vegfaxxxb transcripts: evidence of absence by unbiased RNA-seq analysis. 215	  
As detailed above, the most parsimonious explanation for the lack of Vegfaxxxb PCR products is 216	  
that such transcripts do not exist. However, a theoretical possibility remains that failure to detect 217	  
Vegfaxxxb transcripts results from the targeted nature of the approach (also see BOX2). If so, the 218	  
analysis of RNA datasets obtained through the use of an alternative, unbiased methodology, such 219	  
as RNA-seq, should clarify this matter. Indeed, “RNA-seq represents the method of choice for 220	  




Therefore, we investigated existence of Vegfaxxxb transcripts in publicly available RNA-seq 223	  
datasets generated from multiple human tissues [29]. Our extensive analysis confirmed all 224	  
known Vegfa splice variants and also identified novel transcripts. In particular >40000 Vegfa 225	  
transcripts were uncovered that spanned the junction between exon 7 and exon 8 in >10 different 226	  
human tissues. None of these reads supported the existence of an exon 8b splice site [29]. 227	  
 228	  
We then analysed two independent RNA-seq datasets of hypothalamus / pituitary from castrated 229	  
rams [57] and ovariectomized, estradiol-implanted ewes [56]. This analysis confirmed that Vegfa 230	  
splice variants are phylogenetically conserved, as transcripts identified in sheep correspond to 231	  
those present in human [33]. Indeed, we also identified several novel ovine Vegfa transcripts that 232	  
correspond to those identified by Bridgett et al in human [29]. Crucially, we identified 2693 233	  
Vegfa transcripts that cover the junction between exon 5 and exon 8 or between exon 7 and exon 234	  
8. None of the reads supported the existence of an exon 8b splice site, hence the existence of 235	  
ovine Vegfaxxxb transcripts [33]. These findings [33] rule out the proposed role for VEGFAxxxb 236	  
isoforms in the control of ovine seasonal breeding proposed by Castle-Miller et al [58]. We 237	  
further note that the 43bp-long reverse primer (see Table S1), as provided in the erratum of the 238	  
aforementioned study [58] to “specifically” amplify Vegfa165b by qPCR, would indeed lead to 239	  
co-amplification of the classical Vegfa165 isoform, as its sequence is complementary to a stretch 240	  
of exon 8 located downstream of the putative distal splice site. This implies that qPCR would 241	  
yield two amplicons, which makes the primer pair inadequate for this use and leads to questions 242	  
on the validity of the data published by Castler-Miller et al [58]. In summary, the failure to 243	  
detect Vegfaxxxb mRNA in human and ovine RNA-seq data strongly suggests that these 244	  
transcripts do not exist (also see BOX3). 245	  
 246	  
No Vegfaxxxb transcripts: detection of VEGFAxxxb proteins is an artefact. 247	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Absence of endogenous Vegfaxxxb mRNA implies absence of endogenous VEGFAxxxb 248	  
proteins. Consequently, studies which investigated VEGFAxxxb levels in tissues or plasma, 249	  
using anti-VEGFAxxxb antibodies and ELISA kits, or those which relied exclusively on over-250	  
expression or injection of recombinant VEGFAxxxb proteins have questionable physiological 251	  
relevance (see Table S1; e.g. [18,59-74]). 252	  
 253	  
The first antibody against VEGFAxxxb isoforms (MVRL56/1) was developed by Woolard et al 254	  
2004 [15] and was raised against the synthetic peptide TCRSLTRKD which corresponds to the 255	  
nine amino acid C-terminal sequence of human VEGFA165b (see Figure 1C). This peptide is 256	  
only six amino acids different from the peptide that corresponds to the C-terminal sequence of 257	  
VEGFA165 (TCRCDKPRR). This antibody was made commercially available and distributed 258	  
by R&D (MAB3045) and Abcam (Ab149940; [41]). A sandwich ELISA kit that utilizes the 259	  
MAB3045 antibody is also available via R&D (#DY3045) who also supply a recombinant 260	  
human VEGFA165b protein (#3045-VE-025). Interestingly, Abcam removed Ab149940 from 261	  
their catalog in 2015 as it "did not meet the quality criteria". Specifically, the antibody yielded 262	  
"low signal-to-noise ratio in immunofluorescence and detected multiple non-specific bands in 263	  
western-blot" (communication from Abcam). The use of MVRL56/1 for analysis in the same 264	  
tissue has sometimes led to opposite findings. For instance, using normal breast tissue, Catena et 265	  
al [20] found no VEGFAxxxb staining while Qiu et al [75] observed strong staining. When used 266	  
in western-blot studies, MVRL56/1 yields multiple bands (i.e. smear) that span a broad range of 267	  
molecular weights. These bands have been considered to represent monomers, dimers or large 268	  
complexes of VEGFAxxxb isoforms [36,37]. However, definitive evidence that these bands 269	  




As summarized in Table S1, virtually all studies aimed at detection of VEGFAxxxb proteins 272	  
have relied on the use of the MVRL56/1 antibody. Origene Europe also sells a different antibody 273	  
against hVEGFA165b C-Terminal peptide (the exact sequence of the epitope is not provided; 274	  
#DM3615P). Finally, an "Anti-VEGFA111b antibody" has been raised [76] using "synthetic 275	  
peptide fragments of the 8 amino acids CRSLTRKD". Contrary to what the authors claim, this 276	  
antibody would not be specific for the VEGFA111b isoform, since the epitope corresponds to the 277	  
8 amino acid C-terminal sequence shared by all predicted human VEGFAxxxb isoforms. 278	  
 279	  
Surprisingly, the original anti-human VEGFAxxxb antibody (MVRL56/1) has been used to 280	  
demonstrate the presence of VEGFAxxxb in multiple species that do not share the same C-281	  
terminal sequence (see Figure S1). For instance, it has been used in sheep [58] for which the 282	  
predicted sequence for the last 9 amino acids of the C-Terminal would be TCRCLTRKD, 283	  
therefore slightly divergent from that in human (underlined, Cys instead of Ser). This would 284	  
reduce the size of the VEGFAxxxb-specific epitope recognized by the anti-VEGFAxxxb 285	  
antibody to the LTRKD sequence. Having shown that Vegfaxxxb transcripts do not exist, we 286	  
surmised that VEGFAxxxb-like immunostaining is accounted for by cross-reactivity of the 287	  
antibody with one or several protein(s) unrelated to VEGFA but bearing an epitope of similar 288	  
sequence to that of the putative LTRKD sequence of VEGFAxxxb. We searched human protein 289	  
databases using BLASTP, which led to the unambiguous identification of 10 proteins harboring 290	  
an LTRKD motif [33]. The MVRL56/1 anti-human VEGFAxxxb antibody was also used to 291	  
detect endogenous VEGFAxxxb isoforms in tissues from mouse [65,75,77] and rat [45,60], 292	  
species which, as already noted by us and others ([13,28]; see Figure S1), would present a 293	  
distinct CRPLTGKTD motif at the C-term of VEGFAxxxb, divergent from the human sequence. 294	  
Specifically, we found that in mouse, this antibody detects unidentified proteins that can be 295	  
mistaken for VEGFA isoforms and have raised this as a serious concern [28]. These non-specific 296	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proteins were present in mouse cell extracts and their conditioned media as well as mouse 297	  
tissues. Although the suggestion by Bates et al [50] that these findings might be due to 298	  
artefactual detection of mouse IgG could potentially be correct when testing mouse tissues, this 299	  
possibility is excluded in cell culture and serum-free conditioned media. Taken together, we 300	  
conclude that the anti-VEGFAxxxb antibody might cross-react with a large number of 301	  




Concluding remarks 306	  
We have reviewed current evidence for the proposed existence of a Vegfaxxxb family of 307	  
transcripts which would yield VEGFAxxxb proteins bearing anti-angiogenic properties. 308	  
Inadequate PCR methodology which likely led to the erroneous identification of such transcripts 309	  
has been identified and characterized. Multiple published studies, along with our additional 310	  
analyses of RNA-seq data have failed to identify any Vegfaxxxb-specific splicing events. Thus 311	  
we conclude that Vegfaxxxb transcripts do not exist in vivo and therefore challenge the view that 312	  
endogenous VEGFAxxxb proteins have any physiological relevance. Consequently, efforts to 313	  
develop therapeutics to modulate VEGFA activity should not be based upon modification of a 314	  
splicing event that is not supported by evidence. The story of Vegfaxxxb splicing reinforces the 315	  
importance of supporting new findings using orthogonal techniques prior to basing subsequent 316	  
studies upon them (see Outstanding Questions). 317	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 498	  
Glossary 499	  
Alternative splicing: process by which splice sites in precursor (pre)-mRNA are differentially 500	  
selected to produce multiple mRNA and protein isoforms. This process diversifies the functional 501	  
characteristics of genes and drastically expands the potential repertoire of protein variants. 502	  
Nearly all multi-exon genes have at least one splice variant.  503	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VEGFA (Vascular Endothelial Growth Factor A): a key member of the family of growth factors 504	  
which plays a prominent role in angiogenesis - the growth of blood vessels - both in health and 505	  
disease (tumorigenesis and retinopathies). 506	  
5ˊ-tailing: addition of nucleotides on the 5ˊ-end of a PCR primer. These nucleotides are not 507	  
complementary to the target mRNA but do not impair PCR processivity and aid further cloning 508	  




Text BOXES 513	  
BOX1 514	  
Further technical issues with the use of qRT-PCR 515	  
Since primers for standard PCR were not suitable for qPCR, Bates and co-workers developed an 516	  
alternative method, which we might call "indirect subtractive strategy" [25]. This requires the 517	  
use of two distinct primer pairs. The first pair consists of "an exon 7b forward primer and a 3ˊ-518	  
UTR Primer (both pan-VEGF)", the sequences of which were not provided. The second pair of 519	  
primers consists of "an exon 7a forward primer and a reverse primer specific for exon 8a that do 520	  
not detect Vegfaxxxb isoforms". The authors then assume that subtracting what is found with the 521	  
second primer pair (Vegfaxxx only) to what is found with the first primer pair (total Vegfa: 522	  
Vegfaxxx + Vegfaxxxb) yields the amount of Vegfaxxxb. This is an unusual strategy, which is 523	  
likely to be flawed for a number of reasons. The primary concern is that these are two different 524	  
pairs of primers, with different sequences, hence divergent optimal Tm’s, which amplify 525	  
fragments of different lengths and nucleotide composition and therefore have differing 526	  
efficiencies.  The use of qPCR is based on the principle that the number of copies doubles at 527	  
each cycle. This rule is used as a proxy to determine the initial number of copies. Using the 528	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values of the slopes for the calibration curves (see Figure 1 in [25]) for both primer pairs allows 529	  
calculation of an amplification factor (which should ideally be ~2), which informs on the 530	  
efficiency of the qPCR assay. The efficiency should be ~100%, but values between 85-115% are 531	  
usually judged acceptable, providing the dissociation curves are good [78]. The calculated 532	  
efficiency values for the primer pairs used by Varey et al [25] are 83.7% and 71.8%. The 533	  
meaning of this is twofold. First, neither primer pair is appropriate for use in qPCR. Second, 534	  
different efficiencies are enough to generate a difference when data obtained with the two primer 535	  
pairs are compared. A broadly similar technique, but with different primers, was used by the 536	  
same team in a later study [79]. Other issues with RT-PCR and primer design were also found, 537	  
which are detailed in Supplemental text. 538	  
BOX2 539	  
Ruling out potential issues with mRNA secondary structure 540	  
The idea that PCR amplification of Vegfa165b might be difficult due to secondary structure of 541	  
the mRNA in the 3ˊ-UTR has been invoked [9] to explain why we [31,33] and other authors 542	  
[13,79,80] failed to detect these transcripts. The existence of an unusually stable secondary 543	  
structure seems unlikely because most regulatory splicing mechanisms are based on the 544	  
recognition of short degenerate RNA motifs at the exon/intron boundaries rather than secondary 545	  
structures [82,83]. Indeed, bioinformatic analysis of the ribonucleotidic sequence does not 546	  
predict formation of potential hairpins that might inhibit reverse transcription (data not shown). 547	  
Furthermore, classical Vegfaxxx isoforms are readily amplified using primers spanning the 548	  
putative alternative splice site (see main text). There is therefore no evidence to support the 549	  
notion that Vegfaxxxb isoforms, which would lack a 66bp stretch present in Vegfaxxx isoforms, 550	  
would resist PCR amplification. Furthermore, Vegfa165b transcripts expressed from a 551	  
recombinant construct were readily detected by RNA-seq [32] and since the library preparation 552	  
involved both RT and PCR steps, neither are inherently blocked by the transcript secondary 553	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structure. Therefore, the inability to detect an abundant mRNA such as Vegfa165b at least in 554	  
normal tissues by classical RT-PCR can not be explained by the secondary structure of the 555	  
mRNA. 556	  
BOX3 557	  
Further RNA-seq evidence for absence of Vegfaxxxb mRNAs 558	  
Recently developed long read RNA sequencing technologies (e.g. PacBio Iso-Seq and Oxford 559	  
Nanopore Technology) can measure full length mRNA transcripts [85]. Both individual 560	  
alternative splicing events and the co-occurrence of multiple events in transcripts such as Vegfa 561	  
are detected. To determine whether data generated with this newly available approach could 562	  
detect Vegfaxxxb mRNAs we analysed a publicly available dataset [85]. Full length transcripts 563	  
encoding all the commonly reported exon 5 and exon 6 isoforms (VEGFA121, VEGFA165, 564	  
VEGFA189) were present but no evidence of splicing to generate Vegfaxxxb was detected 565	  
(Supplemental Figure S2). A notable feature apparent from this full length transcript data is the 566	  
retention of the intron between exons 3 and 4 in almost 20% of transcripts (which is supported 567	  
by previous EST data). The regulatory potential of such intron retention events has been widely 568	  
discussed [86,87]. Our recent analysis of RNA-seq data from tumours grown from fibrosarcomas 569	  
expressing VEGFA188 [88] has also failed to identify reads corresponding to the exon 7-8b 570	  
splice site, even though endogenous expression of multiple Vegfaxxx isoforms could be detected 571	  
from the stromal cells (Supplemental Figure S3). To better understand the role of alternative 572	  
splicing in the regulation of Vegfa expression, research should be focused upon such events that 573	  
are supported by strong experimental evidence.  574	  
 575	  
Figure Legends 576	  
Figure 1: Structure and sequence of the human Vegfa gene and VEGFAxxx/VEGFAxxxb 577	  
isoforms. A/ Schematic of the human Vegfa gene locus. The gene is comprised of 8 exons. B/ 578	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Schematic of the longest human VEGFA protein (VEGF206, see GenBank accession number 579	  
NM_001171623). The stop-codon (TGA, in red) is located in exon 8 and the sequence of the last 580	  
9 amino acids at the C-terminus of the protein is provided below. The location of flanking PCR 581	  
primers O14I/O16I is also indicated (see panel F). C/ Schematic of the putative human 582	  
VEGFA206b protein (GenBank accession number NM_001033756). The stop-codon (TGA, in 583	  
red) is located in exon 8 – renamed exon 8b due to the usage of a distal splice site – and the 584	  
sequence of the last 9 amino acids at the C-terminus of the protein is provided below. Note that 585	  
only the sequence of the last 6  amino acids at the C-terminus differ between VEGFA and 586	  
VEGFAb isoforms. D/ Nucleotide sequence (from nt 1716 to nt 1808) of the 5ˊ-end of human 587	  
Vegfa exon 8 and deduced amino acid sequences corresponding to the C-term of VEGFAxxx and 588	  
VEGFAxxxb isoforms ; corresponding nucleotide triplets are underlined. The reference sequence 589	  
used for nucleotide annotation is Genbank NM_001171623. The usual splice site (mauve and 590	  
underlined) leading to VEGFAxxx isoforms (as shown in B) and the putative alternative splice 591	  
site (green and underlined) leading to VEGFAxxxb isoforms (as shown in C) are shown. The 592	  
respective stop codons are also shown (red and bold). Also note that exon 8 and exon 8b would 593	  
share an AT dinucleotide sequence at their 5ˊ-end (grey boxes and bold). E/ Schematic of the 594	  
four most abundant classical hVEGFA splicing isoforms and of their corresponding sister 595	  
isoforms of the proposed hVEGFAxxxb family : both families differ only by the alternative use 596	  
of either exon 8a or 8b, as described in panels B and C using VEGFA206 as an example. 597	  
Adapted from Bridgett et al [32]. F/ Agarose gel electrophoresis of PCR products obtained using 598	  
flanking primers O14I/O16I and cDNA from ovine medio-basal hypothalamus (see panel B for 599	  
location). Gel extraction, cloning and sequencing of the three bands revealed products encoding 600	  
ovine homologs of human VEGFA206 and VEGFA189 (562 and 544bp ; sizes too close to be 601	  
separated on the gel), VEGFA165 (490bp) and VEGFA121 (358bp). No single VEGFAxxxb 602	  
PCR product was obtained. For further information, see Lomet et al. [33]. G/ Schematic of the 603	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signaling pathway elicited by VEGFA isoforms. Classical VEGFA proteins bind both VEGFR2 604	  
homodimer and the Neuropilin1 (NRP1) co-receptor while VEGFAxxxb isoforms fail to bind 605	  
NRP1, impairing intracellular transduction pathways. 606	  
 607	  
Figure 2: Issues with RT-PCR primer design: how 5ˊ-tailing led to erroneous identification of 608	  
Vegfaxxxb transcripts. A/ Schematic of the putative junction between exon 7 (blue) and the 609	  
putative exon 8b (green and black) of Vegfaxxxb transcripts and location of the PCR primers 610	  
used to identify Vegfaxxxb transcripts. Note that exon 7 and the AT dinucleotide (green) at the 611	  
end of exon 8 sequences would be common to both classical Vegfaxxx and Vegfaxxxb isoforms. 612	  
The number of non-isoform specific nucleotides is provided in blue; note that this number has 613	  
substantially increased (from 7bp to 17bp) throughout the years (primers P1 through to P7). 614	  
Sequences in orange represent 5ˊ-tailing. Primers P1-P6 are reverse primers while primer P7 is a 615	  
forward primer, as indicated by the arrows. B/ Minimal sequence requirement to obtain PCR 616	  
amplification of ovine Vegfaxxxb-like transcripts through 5ˊ-tailing as defined in Lomet et al 617	  
[33]. The error-prone primer consists of 11 nucleotides in exon 7 and 2-3 nucleotides of exon 8 618	  
(in green, shared by isoforms), then any nucleotide can be added on the 5ˊ-end of the primer 619	  
providing the number is sufficient (6 or more) to reach a Tm compatible with the PCR 620	  
methodology (see Figure 3). Note that this primer design corresponds to primer P4.   621	  
 622	  
Figure 3: Basic principles of PCR and how 5ˊ-tailing is achieved. A/ Principle of standard PCR. 623	  
After reverse transcription, cDNAs are submitted to 30-40 cycles of denaturation/annealing and 624	  
extension during which a pair of primers (forward and reverse) allow efficient amplification of 625	  
the target sequence they flank. B/ To anneal to the cDNA, the melting temperature (Tm) of the 626	  
primer must be higher than the annealing temperature. C/ The Tm of the primer depends on its 627	  
nucleotide composition and its length, with long GC-rich primers having higher Tms than short 628	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AT-rich primers. A series of 3 efficient primers is shown, the one on the top is the shortest. D/ 629	  
The shortest efficient reverse primer as defined in C can be flanked on its 5ˊ-end with a large 630	  
stretch of additional non-specific extra-bases (for instance restriction sites for further cloning 631	  
purposes), which do not anneal to the target and do not impair PCR efficiency and processivity: 632	  
this is 5ˊ-tailing. E/ The additional non-specific 5ˊ-tail is added to the amplicon as the PCR 633	  
progresses. At the end of the 30-40 cycles, all amplicons are flanked with the additional, non-634	  
specific stretch of the reverse primer. 635	  
 636	  
Supplementary Material 637	  
Includes Supplemental Text, Supplemental table S1, Supplemental Figues S1-S3	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  primer	  located	  downstream	  
in	  the	  3’UTR.	  
	   Home	  made	  
Cui	  et	  al	   Am	  J	  Physiol	  Renal	  Physiol	   286:F767-­‐773	   2004	   Human	  /	  Kidney	   Same	  primers	  as	  Bates	  et	  al	  2002.	   	   	  





Perrin	  et	  al	   Diabetologia	   48:2422-­‐2427	   2005	   Human	  /	  Eye	   Same	  primers	  as	  Bates	  et	  al	  2002.	   Home	  made
ELISA	  
	  
Konopatskaya	  et	  al	   Mol	  Vis	   12:626-­‐632	   2006	   Mouse	  /	  Eye	   No	   	   3045-­‐VE-­‐025	  




Cebe	  Suarez	  et	  al	   Cell	  Mol	  Life	  Sci	   63:2067-­‐2077	   2006	   Human	  cell	  line	  	  
(HUVEC)	  
No	   MAB3045	  
	  
Home	  made	  
Ribeiro	  et	  al	   Mol	  Reprod	  Dev	   74:163-­‐171	   2007	   Swine	  /	  Ovary	   VEGF164b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐TCCTGGTGAGAGATCTGCAAG-­‐3’	  
Note	  :	  level	  <<	  VEGF164	  (2
12
	  fold)	  
	   	  
Pritchard-­‐Jones	  et	  al	   Br	  J	  Cancer	   97:223-­‐230	   2007	   Human	  /	  Melanoma	  
tissue	  
VEGF165b	  HindIII	  RS	  -­‐	  exon	  8b/	  7	  	  
-­‐	  Reverse	  primer	  :	  
5’-­‐TTAAGCTTTCAGTCTTTCCTGGTGAGACTGCA-­‐3’	  
Note	  :	  GAT	  missing	  from	  oligo	  ;	  see	  Bates	  et	  al	  2002	  
Invalid	  primer.	  
MAB3045	   	  
Schumacher	  et	  al	   J	  Am	  Soc	  Nephrol	   18:719-­‐729	   2007	   Human	  /	  Kidney	   VEGF	  both	  isoforms	  BamHI	  RS	  –	  3’UTR	  
Reverse	  primer	  :	  5’-­‐ATGGATCCGTATCAGTCTTTCCT-­‐3’	  
Note	  :	  short	  primer,	  theoretical	  fusion	  T°	  =	  41°C	  
	   	  
Ergorul	  et	  al	   Mol	  Vision	   14:1517-­‐1524	   2008	   Rat	  /	  Retina	   No	   Ab14994	   	  
Qiu	  et	  al	   Faseb	  J	   22:1104-­‐1112	   2008	   Mouse	  /	  Various	  
tissues	  
Primers	  use	  to	  «	  detect	  specifically	  the	  transgene	  »	  
Forward	  :	  5’-­‐TCAGCGCAGCTACTGCCATC-­‐3’	  
Reverse	  :	  5’-­‐GTGCTGGCCTTGGTGAGGTT-­‐3’	  
Note	  :	  Forward	  is	  within	  exon3	  and	  Reverse	  is	  within	  exon
!	  actually	  detect	  all	  Vegfa.	  	  
MAB3045	   Yes	  –	  TG	  mice	  
2	  
	  
Invalid	  primers	  !	  Invalid	  screening	  of	  TG	  mice.	  
Bevan	  et	  al	  	   Nephron	  Physiol	   110:57-­‐67	   2008	   Human	  /	  Kidney	   No	   MAB3045	   	  
Kawamura	  et	  al	   Cancer	  Res	   68:4683-­‐4692	   2008	   Cell	  lines	   No	   	   Home	  made	  
Varey	  et	  al	   Br	  J	  Cancer	   98:1366-­‐1379	   2008	   Human	  /	  Colon	   Original	  indirect	  subtractive	  strategy	  :	  
Use	  of	  «	  An	  exon	  7b	  forward	  primer	  and	  a	  3’UTR	  	  
Primer	  (both	  pan-­‐VEGF)	  »	  -­‐	  Sequences	  not	  provided	  
Then	  use	  of	  «	  an	  exon	  7a	  forward	  primer	  and	  a	  	  
reverse	  primer	  specific	  for	  exon	  8a	  that	  did	  not	  	  
detect	  Vegfxxxb	  isoforms	  ».	  	  
Then	  subtraction	  would	  yield	  Vegfxxxb.	  	  
Invalid	  method.	  
MAB3045	   Yes	  
Diaz	  et	  al	   Int	  J	  Cancer	   123	  :1060-­‐1067	   2008	   Human	  /	  Colon	   Same	  primers	  as	  Bates	  et	  al	  2002.	   MRVL56/1	   	  






Rennel	  et	  al	  	   Br	  J	  Cancer	   98:1250-­‐1257	   2008	   Human	  /	  Prostate	  
Mouse	  





Rennel	  et	  al	   Eur	  J	  Cancer	   44:1883-­‐1894	   2008	   Cell	  lines	  
Mouse	  
No	   MAB3045	   Home	  made	  
Miller-­‐Kasprzak	  and	  
Jagodinski	  
Biomed	  Pharmacother	   62:158-­‐163	   2008	   Human	  /	  	  
Lung	  cell	  line	  
VEGF121b	  exon	  5/8b	  -­‐	  Forward	  primer	  :	  
5’-­‐GAAAATCTCTCACCAGGAAA-­‐3’	  
Note	  :	  one	  A	  missing	  from	  oligo.	  
VEGF165b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐GTGAGAGATCTGCAAGTACG-­‐3’	  
MAB3045	   	  














Baltes-­‐Breitwisch	  et	  al	   Reproduction	   140:319-­‐329	   2010	   Rat	  /	  Testes	   Same	  primers	  as	  Artac	  et	  al.	  2009.	   Ab14994	   	  
Catena	  et	  al	   Molecular	  Cancer	   9	  :320	   2010	   Human	  cell	  lines	   VEGF121b	  –	  HindIII	  RS	  –	  exon	  8b/	  exon5	  
Reverse	  primer	  :	  
5’-­‐TTAAGCTTTCAGTCTTTCCTGGTGAGAGATTTTTCTT	  
GTCTTGCTCTATC	  -­‐	  3’	  
VEGF165b	  –	  HindIII	  RS	  –	  exon	  8b/	  exon7	  
Reverse	  primer	  :	  
5’-­‐TTAAGCTTTCAGTCTTTCCTGGTGAGAGATCTGCAA	  
GTACGTTCGTTTAACTC	  -­‐	  3’	  
MAB3045	   Yes	  
3	  
	  
Hua	  et	  al	   Invest	  Ophtalmol	  Vis	  Sci	   51:4282-­‐4288	   2010	   Human	  /	  Eye	   No	   MAB3045	   	  
Magnussen	  et	  al	   Invest	  Ophtalmol	  Vis	  Sci	   51:4273-­‐4281	   2010	   Mouse	  /	  Eye	   No	   MAB3045	   3045-­‐VE-­‐025	  
Nowak	  et	  al	   J	  Biol	  Chem	   285:5532-­‐5540	   2010	   Cell	  lines	   Same	  as	  Nowak	  et	  al	  2008	   MAB3045	   	  
Peiris-­‐Pagès	  et	  al	   J.Pathol	   222:138-­‐147	   2010	   Cell	  lines	   Same	  as	  Nowak	  et	  al	  2008	   MAB3045	   DY3045	  
3045-­‐VE-­‐025	  
Qiu	  et	  al	   J	  Am	  Soc	  Nephrol	   21:1498-­‐1509	   2010	   Cell	  lines	  
Mouse	  
Same	  invalid	  primers	  as	  Qiu	  et	  al	  2008	  to	  	  
«	  detect	  specifically	  the	  transgene	  »	  







Merdzhanova	  et	  al	  	   Oncogene	   29:	  5392-­‐5403	   2010	   Mouse	  &	  Human	  
Cell	  lines	  
VEGF165b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐TGGTGAGAGATCTGCAAGTACGTT-­‐3’	  
	   	  
Zhao	  et	  al	   Exp	  Eye	  Res	   93:921-­‐926	   2011	   Mouse	  /	  Retina	   No	   Ab14994	   	  
Amin	  et	  al	   Cancer	  Cell	   20:768-­‐780	   2011	   Cell	  lines	   Same	  primer	  as	  Nowak	  et	  al	  2008.	   	   	  
Xu	  et	  al	   Gene	   487:143-­‐150	   2011	   Human-­‐Cat-­‐Rabbit-­‐	  
Rat/	  Various	  tissues	  
Human	  :	  VEGF165b	  exon	  8b/	  7	  
Reverse	  primer	  :	  
5’-­‐TGGTGAGAGATCTGCAAGTACGTT-­‐3’	  
Cat	  :	  VEGF165b	  exon	  8b/	  7	  
Reverse	  primer	  :	  
5’-­‐TGGTGAGAGGTCTGCAAGTACGTT-­‐3’	  
Rabbit	  :	  VEGF165b	  exon	  8b/	  7	  
Reverse	  primer	  :	  
5’-­‐CGGTGAGAGGTCTGCAAGTACGTT-­‐3’	  
Rat	  :	  VEGF165b	  exon	  8b/	  7	  
Reverse	  primer	  :	  
5’-­‐GGTGAGAGGTCTGCAAGTACGTT-­‐3’	  
	   	  
Manetti	  et	  al	   Circ	  Res	   109:e14-­‐26	   2011	   Human	  /	  Skin	   Same	  primer	  as	  Rennel	  et	  al.	  2008	   Ab14994	   	  
Baba	  et	  al	   Dev	  Dyn	   241:595-­‐607	   2012	   Human	  /	  Eye	   VEGF165b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐TCCTGGTGAGAGATCTGCAA-­‐3’	  
Ab14994	   	  
Oltean	  et	  al	   Am	  J	  Physiol	  Renal	  Physiol	   303:F1026-­‐1036	   2012	   Mouse	  /	  Kidney	   Same	  invalid	  primers	  as	  Qiu	  et	  al	  2008	  to	  	  
«	  detect	  specifically	  the	  transgene	  »	  
!	  Invalid	  screening	  of	  TG	  mice.	  
	   TG-­‐mice	  
Qiu	  et	  al	   Reproduction	   143:501-­‐511	   2012	   Marmoset	  /	  Ovary	  
Mouse	  





Clifford	  et	  al	   J	  Immunol	   189:819-­‐831	   2012	   Human	  /	  Cell	  lines	   VEGF165b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐AGAGAGATCTGCAAGTACGTTCG-­‐3’	  
VEGF189b	  exon	  8b/	  7	  -­‐	  Reverse	  primer	  :	  
5’-­‐GTGAGAGATCTGCAAGTACG-­‐3’	  
	   	  




Beazley-­‐Long	  et	  al	   Am	  J	  Pathol	   183:918-­‐929	   2013	   Human	  /	  Brain	  
Rat	  /	  Brain	  
No	   MAB3045	   3045-­‐VE-­‐025	  
Gu	  et	  al	   Biochem	  Biophys	  Res	  Comm	   441:18-­‐24	   2013	   Human	  /	  Cell	  lines	   VEGF111b	  –	  «	  Reverse	  primer	  »	  :	  
5’	  –	  AATGCAGATGTGACAAGCCGAG	  –	  3’	  
Actually	  a	  forward	  primer	  at	  junction	  exon4/8a.	  
Invalid	  !	  Identification	  of	  Vegf111b	  invalid.	  
VEGF165b	  HindIII	  RS	  -­‐	  exon	  8b/	  7	  	  









Delcombel	  et	  al	   Angiogenesis	   16:353-­‐371	   2013	   HEK293	  cells	   VEGF111b	  exon8b/4–	  Reverse	  primer	  :	  
5’-­‐TCCTGGTGAGAGATCTGCATTCAC-­‐3’	  
VEGF121b	  exon8b/5–	  Reverse	  primer	  :	  
5’-­‐GTCTTTCCTGGTGAGAGAGTTTTCTT-­‐3’	  
Note	  :	  primer	  issue	  !	  AT	  missing	  between	  exon8b	  and	  
exon5.	  Invalid.	  
VEGF165b	  exon8b	  –	  Reverse	  primer	  :	  
5’-­‐CGATCGTTCTGTATCAGTCTTTCCT-­‐3’	  
Note	  :	  internal	  to	  exon	  8	  !	  PCR	  product	  =	  classical	  mVEG
Invalid.	  
	   	  
Hulse	  et	  al	   Neurobiol	  Dis	   71:245-­‐259	   2014	   	   Strategy	  similar	  to	  Varey	  et	  al	  2008	  but	  different	  	  
Primers	  ;	  «	  primers	  specific	  for	  VEGF-­‐A165a	  »	  are:	  	  
Forward	  primer	  exon	  7:	  	  
5ʹ′-­‐GTTCAGAGCGGAGAAAGCAT-­‐3ʹ′	  
Reverse	  primer	  exon	  8a	  :	  
5ʹ′-­‐	  TCACATCTGCAAGTACGTTCG-­‐3ʹ′	  
!	  This	  primer	  covers	  exon8a/7	  
Ab14994	   DY3045	  
Kikuchi	  et	  al	   Nat	  Med	   20:1464-­‐1471	   2014	   Human	   hVEGF165b	  exon	  8b/7	  -­‐	  Reverse	  primer	  :	  
5’-­‐GTGAGAGATCTGCAAGTACG-­‐3’	  
-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐-­‐	  
mVEGF165b	  exon	  8b/7	  -­‐	  Reverse	  primer	  :	  
5’-­‐CTTTCCGGTGAGAGGTCTGC-­‐3’	  
	   3045-­‐VE-­‐025	  	  
Hulse	  et	  al	   Clin	  Sci	   129:741-­‐756	   2015	   Cell	  culture	  
Rat	  
No	   	   3045-­‐VE-­‐025	  
Oltean	  et	  al	   J	  Am	  Soc	  Nephrol	   26:1889-­‐1904	   2015	   Human	  /	  Kidney	   VEGF165b	  exon	  8b/7	  -­‐	  Reverse	  primer	  :	  
5’-­‐GTGAGAGATCTGCAAGTACG-­‐3’	  
DY3045	   	  
Vencappa	  et	  al	   Am	  J	  Transl	  Res	   7:1032-­‐1044	   2015	   Cell	  culture	  
Mouse	  
No	   Ab14994	   3045-­‐VE-­‐025	  
Li	  et	  al	   J	  Translat	  Med	   13	  :164	   2015	   Human	  cell	  lines	   Same	  primers	  as	  Gu	  et	  al	  2013	   Same	  as	   Yes	  
5	  
	  
Gu	  et	  al	  	  
2013	  
Hulse	  et	  al	  	   Neurobiol	  Dis	   96:186-­‐200	   2016	   Rat	   No	   Ab14994	   	  
Castle-­‐Miller	  et	  al	   Proc	  Natl	  Acad	  Sci	  USA	   114:E2517-­‐2523	   2017	   Sheep	  /	  Pituitary	   Multiple	  issues	  with	  primers	  leading	  to	  an	  erratum.	  




Targets	  a	  sequence	  downstream	  of	  putative	  distal	  splice	  s
located	  in	  exon	  8.	  Non-­‐isoform	  specific.	  






Ved	  et	  al	   Clin	  Sci	  (Lond)	   131:1225-­‐1243	   2017	   Rat	  /	  Retina	   No	   Home	  made
Clone56/8	  
Yes	  
Pruszko	  et	  al	   EMBO	  reports	   18:1331-­‐1351	   2017	   Human	  cell	  lines	   VEGF121b	  exon	  8b/5	  -­‐	  Reverse	  primer	  :	  
5’-­‐CTTTCCTGGTGAGAGATTTTTCTTGTC-­‐3’	  
VEGF165b	  exon	  8b/7	  -­‐	  Reverse	  primer	  :	  
5’-­‐CCTGGTGAGAGATCTGCAAGTAC-­‐3’	  
Ab14994	   	  
Hueso	  et	  al	   Scientific	  Reports	   7	  :9962	   2017	   Human	  	  
Serum	  /	  Heart	  
No	   MAB3045	   MBS109074	  
Chesnokov	  et	  al	   PeerJ	  
	  
6:e4915	   2018	   Human	  /	  Tissues	   VEGFxxxb	  exon	  7/8b	  -­‐	  Forward	  primer	  :	  
5’-­‐ACGTACTTGCAGATCTCTCACCA-­‐3’	  
Underlined	  bases	  correspond	  to	  either	  end	  of	  exon7	  	  
OR	  exon	  8.	  
	   	  
Blochowiak	  et	  al	   Adv	  Clin	  Exp	  Med	   27:83-­‐90	   2018	   Human	  /	  Parotid	   No	   DM3615P	   	  
Boudria	  et	  al	   Oncogene	   AOP	   	   Mice	  /	  Cell	  lines	   No	   Yes	   Yes	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P2 (7bp) - 2002
P3 (9bp) - 2007
P4 (13bp) - 2008
P5 (15bp) - 2009
P6 (17bp) - 2011
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Other methodological issues with RT-PCR 
We noted further inconsistencies in the literature and not-readily-explainable RT-PCR findings. 
First, to identify Vegfa165b, Bates et al [1] used primers designed to detect Vegfa148, a transcript 
identified from kidney by the same team [2] and recently shown to be enriched in some tissues, 
including kidney [3]. The pair of primers used by Bates et al [1] consisted of a forward primer 
located within exon 7a and a reverse primer located in the 3ˊ-UTR, downstream of the putative 
alternative 8b splice site (i.e. flanking primers; Table S1). This should yield at least two PCR 
products of 185bp and 151bp, corresponding to Vegfa165 and Vegfa148. Should the Vegfa165b 
transcript exist, one would expect an extra PCR product at 120bp. Hence, 3 bands should be 
discernible on the gel, with the one corresponding to Vegfa148 located in between those for 
Vegfa165 and Vegfa165b. This was not the case. This is puzzling considering these primers were in 
the first instance "designed to detect Vegfa148". The same issue applies to the study by Schumacher 
et al [4] who used the same primers. Furthermore, Vegfaxxxb transcripts were not identified by 
2	  
	  
Whittle et al [2], who used a pair of ad hoc primers for this (forward primer in exon 7a and reverse 
primer downstream of the putative 8b splice site).  
 
In follow-up studies from the team led by Bates and Harper, DNA rulers were often missing and 
sequencing of the PCR products was not reported [e.g.; 5-8], and therefore the identity of PCR 
products could not be confirmed. Rather, to validate the existence of an entire family, the authors 
used assertions such as "size compatible with Vegfa165b" [9], "bands corresponding to 
VEGFAxxxb isoforms (VEGFA165b, VEGFA189b, etc.) were seen …" [6] but unfortunately not 
shown, or "multiple isoforms were detected, with bands seen consistent with VEGFA121b (108 bp), 
VEGFA145b (219 bp) and VEGFA165b (240 bp)".  In particular, Cui et al [9] used isoform-
specific reverse primers to amplify either Vegfa165 or Vegfa165b. These primers were used in 
combination with the same forward primer, located in exon 4. Therefore RT-PCR for Vegfa165 is 
expected to yield at least 3 major bands. Considering the "sister family of Vegfaxxxb", RT-PCR for 
Vegfa165b should yield all transcripts that include exon 7b (at least Vegfa189b and Vegfa165b). 
However, only products of "sizes compatible with" the presence of Vegfa189 and Vegfa165b were 
evident on the gel (see [9]; their Fig.3).  
 
Finally, primers used to "detect specifically the transgene" [10,11] in a transgenic mouse model, 
which over-expresses Vegfa165b in the mammary gland, are located within exon3 (forward primer) 
and exon4 (reverse primer). Therefore, this primer pair will detect all Vegfa isoforms (see Table 
S1), which casts doubts on this mouse model. 
1 Bates, D.O. et al. (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-
regulated in renal cell carcinoma. Cancer Res 62, 4123-4131  
2 Whittle, C. et al. (1999) Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor 
mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. 
Clin Sci (Lond) 97, 303-312  
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3 Bridgett, S. et al. (2017) RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of 
VEGFAxxxb isoforms. Sci Rep 7, 58-017-00100-3  
4 Schumacher, V.A. et al. (2007) Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J 
Am Soc Nephrol 18, 719-729  
5 Woolard, J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of 
action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64, 7822-7835  
6 Perrin, R.M. et al. (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic 
isoforms of vascular endothelial growth factor. Diabetologia 48, 2422-2427  
7 Bates, D.O. et al. (2006) The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-
regulated in pre-eclamptic placentae at term. Clin Sci (Lond) 110, 575-585  
8 Peiris-Pages, M. et al. (2010) Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth 
factor as a regulator of neuroblastoma growth. J Pathol 222, 138-147  
9 Cui, T.G. et al. (2004) Differentiated human podocytes endogenously express an inhibitory isoform of vascular 
endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol Renal Physiol 286, F767-73  
10 Qiu, Y. et al. (2008) Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic 
growth factor isoform, VEGF165b. Faseb j 22, 1104-1112  
11 Qiu, Y. et al. (2010) Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 
21, 1498-1509  
 
Antibodies and ELISA kits (see text and Supplemental Table1): 
-­‐ MAB3045	   from	   R&D	  :	  Monoclonal	  Mouse	   IgG1	   Clone	   #	   56-­‐1	  ;	   directed	   against	   human	   VEGF165b	  
synthetic	  peptideTCRSLTRKD.	  
https://www.rndsystems.com/products/human-­‐vegf-­‐165b-­‐antibody-­‐56-­‐1_mab3045	  
Note	  :	   another	   Ab	   (raised	   against	   the	   same	   9	   amino	   acids)	   from	   clone	   #264610/1	   was	   used	   in	  
Nowak	  et	  al	  2008	  –	  no	  further	  information	  could	  be	  found.	  
Note	  :	  for	  Castle-­‐Miller	  et	  al	  2017	  and	  Ved	  et	  al	  2017	  another	  clone	  (56/8)	  was	  used.	  No	  validation	  
provided.	  
-­‐ DM3615P	   from	   Origene	  :	   Monoclonal	   Mouse	   IgG1	   Clone	   #7F17	  ;	   directed	   against	   human	  
recombinant	  Human	  VEGF-­‐165b	  C-­‐terminal	  peptide	  
https://www.acris-­‐anticorps.fr/antibodies/primary-­‐antibodies/vegf165b-­‐dm3615p.htm	  
-­‐ DY3045	  from	  R&D	  :	  human	  VEGF165b	  Solid	  Phase	  Sandwich	  ELISA	  
https://www.rndsystems.com/products/human-­‐vegf-­‐165b-­‐duoset-­‐elisa_dy3045#product-­‐details	  
-­‐ 3045-­‐VE-­‐025	  :	  Recombinant	  human	  VEGFA165b	  protein	  
https://www.rndsystems.com/products/recombinant-­‐human-­‐vegf-­‐165b-­‐protein_3045-­‐ve	  
-­‐ Ab14994	  (clone	  MRVL56/1)	  from	  Abcam	  :	  mouse	  monoclonal	  antibody	  –	  discontinued	  since	  2015.	  
https://www.abcam.com/vegf165b-­‐antibody-­‐mrvl561-­‐ab14994.html	  







List	  of	  additional	  references	  only	  cited	  in	  Supplemental	  Table1	  :	  
1 Amin, E.M. et al. (2011) WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF 
splicing. Cancer Cell 20, 768-780  
2 Baltes-Breitwisch, M.M. et al. (2010) Neutralization of vascular endothelial growth factor antiangiogenic isoforms or 
administration of proangiogenic isoforms stimulates vascular development in the rat testis. Reproduction 140, 319-329  
3 Hueso, L. et al. (2017) Dynamics and implications of circulating anti-angiogenic VEGF-A165b isoform in patients 
with ST-elevation myocardial infarction. Sci Rep 7, 9962-017-10505-9  
4 Li, X. et al. (2015) VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian 
cancer growth. J Transl Med 13, 164-015-0522-0  
5 Nowak, D.G. et al. (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by 
splicing and growth factors. J Cell Sci 121, 3487-3495  
6 Nowak, D.G. et al. (2010) Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to 
anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 285, 5532-5540  
7 Qiu, Y. et al. (2010) Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol 
21, 1498-1509  
8 Stevens, M. et al. (2018) Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water 





CCA/CCG/CCC/CCT = Proline. 
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